Search
This review outlines a clinical development strategy detailing the phases of development required for registration of a candidate Group A streptococci vaccin
Echocardiographic screening for rheumatic heart disease is cost-effective in our context
The prognosis of young Indigenous Australians diagnosed with severe RHD is bleak; interventions must focus on earlier detection and treatment
We aimed to review RHD burden in Western Pacific Region outside Oceania to identify countries with high RHD burden
A sample target product profile for reformulated benzathine penicillin G is presented
Adverse outcomes for people with acute rheumatic fever and rheumatic heart disease and the effect of comorbidities and demographic factors on these outcomes
Head, Strep A Translation; Co-Founder of REACH
As Head of Aboriginal Research Development at Telethon Kids, Glenn Pearson believes his work brings us closer to identifying the real and whole Australian story
New research has revealed that molecular point-of-care testing (POCT) can significantly improve detection of Group A Streptococcal (Strep A) pharyngitis compared to laboratory culture – particularly in remote communities, where results can take up to seven days – unlocking a major opportunity to prevent rheumatic
A team led by Dr Joseph Kado from the Wesfarmers Centre of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, and The University of Western Australia (UWA) has been awarded $5 million by the Federal Government in a major push to prevent rheumatic heart disease across the Pacific.